Compare BridgeBio Pharma Inc (BBIO) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs PepsiCo, Inc. — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while PepsiCo, Inc. trades at $135.8 (market cap $184.87B). The key difference: PepsiCo, Inc. is far larger — about 11.2× BridgeBio Pharma Inc's market cap, and PepsiCo, Inc. pays a 4.37% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | PEP | |
|---|---|---|
Market Cap | $16.46B | $184.87B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $170.44 |
52-Week Low | $44.81 | $133.81 |
Enterprise Value | $18.02B | $227.37B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
PepsiCo (PEP) trades at $138.49, up 0.81% with a bearish technical signal despite strong fundamentals. The company reported three consecutive quarterly EPS beats and maintains robust profitability with 10.78% net margin and 51.59% ROE. Recent news highlights price adjustments on snack products and sponsorship withdrawals, while analysts maintain a consensus price target of $159.27 with 33% buy ratings.
PEP offers stable dividend income and consistent earnings growth potential, though near-term technical weakness and pricing strategy adjustments present headwinds. The stock trades at reasonable valuation multiples (P/E 17.75) with upside to analyst targets, but investors should monitor North American performance recovery and consumer pricing sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
